Does the concomitant intra-arterial injection of asialoerythropoietin and edaravone mitigate ischaemic mucosal damage after acute superior mesenteric artery thromboembolism in a rabbit autologous fibrin clot model?
To increase the survival rate of patients with acute superior mesenteric artery thromboembolism (ASMAT) treated by catheter thrombolysis, we examined the effects of delivering edaravone and asialoerythropoietin, agents with tissue-protective activities, using a rabbit autologous fibrin clot ASMAT model. Japanese white rabbits (n=32) were randomly separated into four equal groups. 45 min after introducing autologous fibrin clot, Group U received urokinase and heparin; Group E received urokinase and heparin plus edaravone; Group A received urokinase and heparin plus asialoerythropoietin; and Group EA received urokinase, heparin and edaravone plus asialoerythropoietin via a catheter. The intestines were removed 6 h later and intestinal mucosal damage was scored using the Park's injury score. Survival time was assessed. Average mucosal injury was 5.78+/-1.52 (Group U), 2.88+/-0.72 (Group E), 1.90+/-1.23 (Group A) and 1.18+/-1.25 (Group EA). The degree of mucosal injury was significantly lower in Group EA than in Groups U and E (p<0.05). Conversely, there was no significant difference between Group A and Group EA, or between Group A and Group E. The survival times were 31.50+/-13.30 h (Group U), 51.00+/-24.74 h (Group E), 48.00+/-16.97 h (Group A) and 82+/-51.07 h (Group EA); the difference among the four groups was not significant. In conclusion, the concomitant administration of asialoerythropoietin and edaravone reduced mucosal membrane injury significantly compared with edaravone alone. However, to improve the survival of ASMAT rabbit models, the delivery of an appropriate dose of asialoerythropoietin is required, together with the development of methods to assess peripheral recanalisation.
Sonoda
A
A
Department of Radiology, Shiga University of Medical Science, Shiga, Japan. akinaga@belle.shiga-med.ac.jp
Nitta
N
N
Seko
A
A
Ohta
S
S
Takemura
S
S
Sugimoto
T
T
Uzu
T
T
Yokomaku
Y
Y
Takahashi
M
M
Kashiwagi
A
A
Murata
K
K
D000818:Animals; D000983:Antipyrine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D001212:Asialoglycoproteins / Q000008:administration & dosage* / Q000494:pharmacology; D002404:Catheterization; D004195:Disease Models, Animal; D004338:Drug Combinations; D000077553:Edaravone; D004921:Erythropoietin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D005337:Fibrin; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D016166:Free Radical Scavengers / Q000008:administration & dosage* / Q000494:pharmacology; D006493:Heparin / Q000627:therapeutic use; D007269:Injections, Intra-Arterial; D007413:Intestinal Mucosa / Q000473:pathology; D017538:Mesenteric Artery, Superior; D008641:Mesenteric Vascular Occlusion / Q000150:complications* / Q000188:drug therapy / Q000401:mortality; D011817:Rabbits; D011897:Random Allocation; D015427:Reperfusion Injury / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D015996:Survival Rate; D013923:Thromboembolism / Q000150:complications* / Q000188:drug therapy / Q000401:mortality; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
D001212:Asialoglycoproteins; D004338:Drug Combinations; D005343:Fibrinolytic Agents; D016166:Free Radical Scavengers; C500605:asialoerythropoietin; D004921:Erythropoietin; D005337:Fibrin; D006493:Heparin; D014568:Urokinase-Type Plasminogen Activator; D000077553:Edaravone; D000983:Antipyrine